Use of Dipeptidyl Peptidase-4 Inhibitors for the Treatment of Patients with Type 2 Diabetes Mellitus and Chronic Kidney Disease

References

• . Ninomiya I, Perkovic V, de Galan BE, ; ADVANCE Collaborative Group. Albuminuria and kidney function independently predict cardiovascular and renal outcomes in diabetes. J Am Soc Nephrol. 2009;20(8):1813–1821
   PubMed Web of Science ®Google Scholar
• . Nathan DM, Buse JB, Davidson MB, ; American Diabetes Association; European Association for Study of Diabetes. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2009;32(1):193–203
   PubMed Web of Science ®Google Scholar
• . Glucophage (metformin hydrochloride) [package insert]. Princeton, NJ: Bristol-Myers Squibb; 2009
   Google Scholar
• . Lubowsky ND, Siegel R, Pittas AG. Management of glycemia in patients with diabetes mellitus and chronic kidney disease. Am J Kid Dis. 2007;50(5):865–879
   PubMedGoogle Scholar
• . Holstein A, Plaschke A, Hammer C, Egberts EH. Characteristics and time course of severe glimepiride- versus glibenclamide-induced hypoglycemia. Eur J Pharmocol. 2003;59(2):91–97
   Google Scholar
• . Abe M, Okada K, Soma M. Antidiabetic agents in patients with chronic kidney disease and end-stage renal disease on dialysis: metabolism and clinical practice. Curr Drug Metab. 2011;12(1):57–69
   PubMedGoogle Scholar
• . Mikhail N. Why should we avoid the use of rosiglitazone? South Med J. 2008;101(3):329–331
   PubMedGoogle Scholar
• . Ramirez SP, Albert JM, Blayney MJ, . Rosiglitazone is associated with mortality in chronic hemodialysis patients. J Am Soc Nephrol. 2009;20(5):1094–1101
   PubMedGoogle Scholar
• . Byetta (exenatide) [package insert]. San Diego, CA: Amylin Pharmaceuticals; 2009
   Google Scholar
• . Victoza (liraglutide) [package insert]. Princeton, NJ: Novo Nordisk; 2010
   Google Scholar
• . Mikhail N. Incretin mimetics and dipeptidyl peptidase inhibitors in clinical trials for the treatment of type 2 diabetes. Expert Opin Investig Drugs. 2008;17(6):845–853
   PubMed Web of Science ®Google Scholar
• . Shurraw S, Hemmelgarn B, Lin M, ; Alberta Kidney Disease Network. Association between glycemic control and adverse outcomes in people with diabetes mellitus and chronic kidney disease. Arch Intern Med. 2011;171:1920–1927
   PubMedGoogle Scholar
• . Davis TM, Brown SG, Jacobs IG, Bulsara M, Bruce DG, Davis WA. Determinants of severe hypoglycemia complicating type 2 diabetes: the Fremantle diabetes study. J Clin Endocrinol Metab. 2010;95 (5):2240–2247
   PubMedGoogle Scholar
• . Scheen AJ. Pharmacokinetics of dipeptidylpeptidase-4 inhibitors. Diabetes Obes Metab. 2010;12(8):648–658
   PubMed Web of Science ®Google Scholar
• . Januvia (sitagliptin) [package insert]. Whitehouse Station, NJ: Merck & Co, Inc; 2011
   Google Scholar
• . Januvia [package insert]. European Medicines Agency. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000722/WC500039054.pdf. Accessed June 19, 2012
   Google Scholar
• . Novartis Pharmaceuticals UK Ltd. Galvus UK. Summary of product characteristics. Camberley. Surrey, UK. January 2011. http://www.medicines.org.uk/emc/medicine/20734/SPC/. Accessed June 19, 2012
   Google Scholar
• . Onglyza (saxagliptin) [package insert]. Princeton, NJ: Bristol-Myers Squibb; July 2009
   Google Scholar
• . Tradjenta (linagliptin) [package insert]. Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals, Inc; 2011
   Google Scholar
• . Graefe—Mody U, Friedrich C, Port A, . Effect of renal impairment on the pharmacokinetics of the dipeptidyl peptidase-4 inhibitor linagliptin. Diabetes Obes Metab. 2011;13(10):939–946
   PubMed Web of Science ®Google Scholar
• . Lukashevich V, Schweizer A, Shao Q, Groop PH, Kothny W. Safety and efficacy of vildagliptin versus placebo in patients with type 2 diabetes and moderate or severe renal impairment: a randomized placebo-controlled trial. Diabetes Obes Metab. 2011;13(10):947–954
   PubMedGoogle Scholar
• . Ito M, Abe M, Okada K, . The dipeptidyl peptidase-4 (DPP-4) inhibitor vildagliptin improves glycemic control in type 2 diabetic patients undergoing hemodialysis. Endocr J. 2011;58(11):979–987
   PubMedGoogle Scholar
• . Nowicki M, Rychlik I, Haller H, . Long-term treatment with the dipeptidyl peptidase-4 inhibitor saxagliptin in patients with type 2 diabetes mellitus and renal impairment: a randomised controlled 52-week efficacy and safety study. Int J Clin Pract. 2011;65(12):1230–1239
   PubMed Web of Science ®Google Scholar
• . Chan JC, Scott R, Arjona Ferreira JC, . Safety and efficacy of sitagliptin in patients with type 2 diabetes and chronic renal insufficiency. Diabetes Obes Metab. 2008;10:545–555
   PubMed Web of Science ®Google Scholar
• . Mikhail N. Safety of dipeptidyl peptidase 4 inhibitors for treatment of type 2 diabetes. Curr Drug Saf. 2011;6(5):304–309
   PubMedGoogle Scholar
• . Nauck MA, Meininger G, Sheng D, Terranella L, Stein PP; Sitagliptin Study 024 Group. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double-blind, non-inferiority trial. Diabetes Obes Metab. 2007;9(2):194–205
   PubMed Web of Science ®Google Scholar
• . Mikhail N. Combination therapy with DPP-4 inhibitors and pioglitazone in type 2 diabetes: theoretical consideration and therapeutic potential. Vasc Health Risk Manag. 2008;4(6):1–7
   PubMedGoogle Scholar
• . Williams—Herman D, Engel SS, Round E, . Safety and tolerability of sitagliptin in clinical studies: a pooled analysis of data from 10,246 patients with type 2 diabetes. BMC Endocr Disord. 2010;10:7
   PubMed Web of Science ®Google Scholar
• . Schweizer A, Dejager S, Foley JE, . Assessing the cardio-cerebrovascular safety of vildagliptin: meta-analysis of adjudicated events from a large phase III type 2 diabetes population. Diabetes Obes Metab. 2010;12(6):485–494
   PubMed Web of Science ®Google Scholar
• . Scirica BM, Bhatt DL, Braunwald E, . The design and rationale of the saxagliptin assessment of vascular outcomes recorded in patients with diabetes mellitus—thrombolysis in myocardial infarction (SAVOR-TIMI) 53 Study. Am Heart J. 2011;162(5):818–825
   PubMed Web of Science ®Google Scholar
• . Jose T, Inzucchi SE. Cardiovascular effects of the DPP-4 inhibitors. Diab Vasc Dis Res. 2012;9(2):109–116
   PubMed Web of Science ®Google Scholar
• . Gooben K, Graber S. Longer-term safety of dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes mellitus: systematic review and meta-analysis [published online ahead of print April 20, 2012]. Diabetes Obes Metab.
   Google Scholar
• . Budde K, Neumayer H, Fritsche L, . The pharmacokinetics of pioglitazone in patients with impaired renal function. Br J Clin Pharmacol. 2003;55(4):368–374
   PubMed Web of Science ®Google Scholar
• . Schneider CA, Ferrannini E, DeFronzo R, . Effect of pioglitazone on cardiovascular outcome in diabetes and chronic kidney disease. J Am Soc Nephrol. 2008;19(1):182–187
   PubMedGoogle Scholar
• . Manley HJ, Allock NM. Thiazolidinedione safety and efficacy in ambulatory patients receiving hemodialysis. Pharmacotherapy. 2003;23(7):861–865
   PubMed Web of Science ®Google Scholar
• . Kermani A, Garg A. Thiazolidinedione-associated congestive heart failure and pulmonary edema. Mayo Clin Proc. 2003;78(9): 1088–1091
   PubMedGoogle Scholar
• . Azoulay L, Yin H, Filion KB, . The use of pioglitazone and the risk of bladder cancer in people with type 2 diabetes: nested case-control study. BMJ. 2012;344:e3645
   PubMed Web of Science ®Google Scholar